跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

Y0000527

罗库溴铵

European Pharmacopoeia (EP) Reference Standard

别名:

罗库溴铵 溴化物

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C32H53BrN2O4
CAS号:
119302-91-9
分子量:
609.68
MDL號碼:
MFCD00867768
分類程式碼代碼:
41116107
PubChem物質ID:
329831004
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

rocuronium

製造商／商標名

EDQM

溶解度

H2O: 100 mg/mL, clear, light yellow

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

−20°C

SMILES 字串

[Br-].CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCOCC5)[N+]6(CCCC6)CC=C

InChI

1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1

InChI 密鑰

OYTJKRAYGYRUJK-FMCCZJBLSA-M

基因資訊

human ... CHRNA1(1134) , CHRNB1(1140) , CHRND(1144) , CHRNE(1145) , CHRNG(1146)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Rocuronium for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化／生理作用

Aminosteroid; neuromuscular blocker for anaesthesia

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Skull and crossbones
GHS06

訊號詞

Danger

危險聲明

H301,H335

危險分類

Acute Tox. 3 Oral - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Adrienn Pongrácz et al.
Anesthesiology, 119(1), 36-42 (2013-05-15)
Doses of sugammadex required to reverse deep, moderate, and shallow rocuronium-induced neuromuscular blockade have been established. However, no adequate doses for the reversal of reappearance of four twitches of train-of-four (TOF) stimulation (threshold TOF-count-four) have been established. This single-center, randomized
Low-dose sugammadex reversal: there is no such thing as a free lunch.
Aaron F Kopman et al.
Anesthesiology, 119(1), 10-12 (2013-05-15)
Yuji Kadoi et al.
The journal of ECT, 29(1), 33-36 (2012-10-12)
This study was conducted to (1) compare the recovery times from rocuronium-induced muscle relaxation after reversal with sugammadex between young and elderly patients undergoing electroconvulsive therapy (ECT), and (2) to examine the existence of a correlation between cardiac index and
Yian Xing et al.
The Journal of surgical research, 185(1), 198-205 (2013-07-03)
Muscles innervated by the facial nerve show different sensitivities to muscle relaxants than muscles innervated by somatic nerves, especially in the presence of facial nerve injury. We compared the evoked electromyography (EEMG) response of orbicularis oris and gastrocnemius in with
P H M Sadleir et al.
Anaesthesia and intensive care, 42(1), 93-96 (2014-01-30)
Sugammadex is a selective binding agent for aminosteroid neuromuscular blockers whose use is increasing in anaesthetic practice. We present three cases of severe anaphylaxis coincident with sugammadex administration. Subsequent intradermal testing confirmed sugammadex as the triggering agent, with all patients
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门